INTRODUCTION
Non-vitamin K antagonist direct oral anticoagulants (DOACs) have recently been introduced into clinical use for prevention of stroke in patients with non-valvular atrial fibrillation and treatment of patients with deep vein thrombosis or pulmonary emboli. (1-7) The DOACs are renally excreted and dosing recommendations for prevention of stroke in patients with nonvalvular atrial fibrillation are based on renal clearance estimated by the Cockcroft and Gault equation (8) (dabigatran, rivaroxaban, and edoxaban), age (apixaban), weight (apixaban, edoxaban), and creatinine (apixaban, edoxaban), concomitant administration of strong Pglycoprotein inhibitors or inducers (dabigatran, rivaroxaban, apixaban, edoxaban), and presence of cirrhosis (by Child-Pugh class (9) ). Currently, most clinical laboratories report estimated glomerular filtration rate (GFR) and not estimated creatinine clearance. Estimation equations for creatinine clearance and GFR differ in values assigned to age, sex, weight, and race and were derived from different clinical populations. (8, (10) (11) (12) The majority of patients with atrial fibrillation are elderly and creatinine clearance estimates predict a steeper decline with advancing age than GFR estimates. This raises the possibility that substitution of commonly reported GFR for estimated creatinine clearance could result in selection of a dose that differs from recommended dosing guidelines. The purpose of this study was to compare estimates of creatinine clearance and GFR and determine the extent to which calculated doses would differ if GFR were used in place of estimated creatinine clearance. 
METHODS
Overall Design. Simulation using NHANES 2011-2012 data and a research database to calculate GFR and creatinine clearance followed by analysis of differences in dosing recommendations if GFR were substituted for creatinine clearance. coefficient. The relationship between differences in CrCL-CG and GFR estimates in relation to age and weight were graphically examined and then tested by multiple regression for independent effects and ANOVA for interactions.
Definition of Recommended Doses. Dosage information from FDA-approved package inserts was defined as the recommended dose. Adjustments for creatinine clearance when prescribed for stroke prevention in non-valvular atrial fibrillation are: dabigatran reduce dose for CrCL-CG of 15-30 ml/min (to 75 mg twice daily vs. 150 mg twice daily), rivaroxaban reduce dose for CrCL-CG of 15 to 49 ml/min (to 15 mg once daily vs 20 mg), edoxaban reduce dose for CrCl of 30 to 49 ml/min (to 30 mg daily from 60 mg once daily) with edoxaban not recommended for CrCL-CG >95 ml/min. Apixaban was not included in analyses as recommended dose reductions are not based on estimated renal clearance but on the presence of at least two of the following criteria: age 80y or older, weight 60 kg or less, and serum creatinine of 1.5mg/dL or greater, and co-medications.
Differences in Doses calculated by GFR as compared to CrCL-CG. Raw numbers and percents
of subjects with differences between estimates of GFR and CrCL-CG that would have resulted in a dosing difference are presented.
RESULTS

Subject
Data. Demographic and laboratory results are presented in Table 1 . NHANES civilian non-institutionalized adults had a younger mean age and slightly higher proportion of blacks than the research subjects while mean weight and serum creatinine were similar. Independent of method, mean estimates of renal clearance were lower in the research subject sample compared to the NHANES sample ( Table 1) . Estimates of creatinine clearance and glomerular filtration by all methods were highly correlated (p<.0001) with stronger correlations between glomerular filtration estimates than between estimates of creatinine clearance and glomerular filtration.
Although not routinely performed, correction of glomerular filtration estimates for body surface area improved correlations with creatinine clearance estimates. (see Appendix Table 1 for between method correlations). Table 2 In the NHANES sample 28 per cent of subjects with creatinine clearances below 50 ml/min would not be correctly classified using any of the GFR equations (even after body surface area correction) and 47-56 per cent of research subjects samples would not be correctly classified. For CrCL-CG between 30 and 50 ml/min, the mean overestimate in the NHANE sample using the CKD-EPI equation was 4.9 with a S.D. of 13.3 and 5 ± 13.4 for the MDRD equation. For research subjects, the overestimation was greater with a mean of 14.5 ±12.8 using the CKD-EPI equation and 18.8 ±15.1 using the MDRD equation. Although fewer subjects in either sample had creatinine clearances below 30 ml/min, similar proportions of GFR overestimation were seen (18-21% of NHANES subjects and in 43-86% of research subjects depending on the method, see Table 2 ). Very few subjects had creatinine clearances below 15 ml/min for which dabigatran, edoxaban, and rivaroxaban are not recommended and GFR estimates correctly identified these individuals (1 in the research sample and 10 in NHANES).
A CrCL-CG over 95 ml/min identifies patients with non-valvular atrial fibrillation for whom edoxaban is not currently indicated. Table 2 and Figure 2 present comparisons of creatinine clearance and GFR estimates for subjects with creatinine clearances over 95 ml/min. Almost In both the NHANES and research samples, weight (p<.0001) and age (p<.0001) contributed to differences between creatinine clearance and GFR estimates with weight explaining more of the difference. Plots of differences of individual renal clearance estimates by age and weight are presented in Figure 3 . Individuals with lower weights had higher estimated GFR compared to creatinine clearance and individuals with higher weights had lower GFR estimates than creatinine clearance estimates. Age effects were characterized by higher GFR compared to CrCL-CG in older adults and lower GFR compared to CrCL-CG in younger adults. In the NHANES sample there was greater racial diversity and a race effect was detected on the differences between estimates (p<.0042) with interactions detected between sex and weight (p<.0001), race and weight p(<.0001), and sex, weight and age (p=.0065). In the smaller research sample, weaker interactions between sex and weight (p<.03) and sex*age*weight (p<.03) were detected with insufficent racial diversity for analyses.
Although overall correlation between estimates of creatinine clearance and GFR improved after correction for body surface area, correction for body surface area did not reduce misclassification of subjects with creatinine clearance rates below 30 or below 50 ml/min for whom DOAC dose reductions would be recommended. (Table 2 ). In contrast to results at lower creatinine clearances, correction of GFR estimates for body surface area greatly reduced misclassifications of subjects with creatinine clearance over 95 ml/min (i.e., who would be ineligible for edoxaban). The present work examined data from adults in the large NHANES sample of civilian noninstitutionalized U.S. residents and a group of research subjects including community-dwelling and nursing home residents who were medically stable but included very elderly and frail. In agreement with NKDEP conclusions, in the NHANES sample of young and middle-aged adults with fewer elderly and very elderly, the majority had estimated creatinine clearances that were not in the range of recommended DOAC dosage adjustments and CrCL-CG and GFR estimates were more likely to be concordant. The research subject sample had a mean estimated creatinine clearance that was lower and a greater proportion demonstrated differences between CrCL-CG and GFR (CKD-EPI). Differences were characterized by higher estimates of GFR than creatinine clearance at older ages and in people at lower weights and lower estimates of GFR than creatinine clearance in people with higher weights. However, rather than population differences or examining accuracy of the algorithms, the focus of this work was on determining the potential effects that differences in estimates of creatinine clearance and GFR would have on recognition of a need for dose reduction or choice of a DOAC for stroke prevention in an individual with non-valvular atrial fibrillation. For rivaroxaban and edoxaban, dose reductions are recommended for patients with creatinine clearance below 50 ml/min and for dabigatran reduced doses are recommended at a creatinine clearance below 30 ml/min. The data show that if GFR (as MDRD or CKD-EPI) were substituted for creatinine clearance estimates, from one fifth to one half of people that should receive a reduced dose of a DOAC would not be identified.
The National Kidney Disease Education Program (NKDEP) concludes that for most drugs, adjusting for BSA is not necessary for determining drug dosing. However, if using GFR in very large or very small patients, the reported GFR should be multiplied by the body surface area to obtain GFR in units of ml/min. (http://nkdep.nih.gov/resources/ckd-drug-dosing-508.pdf).
Despite improved correlations between GFR and CrCL-CG after correction of CKD-EPI
estimates for body surface area, there was little to no improvement in concordance of estimates for creatinine clearances below 50 ml/min or below 30 ml/min for which DOAC dose reductions are recommended. While the DOACs have not been classified as narrow therapeutic window medications, higher concentrations are associated with greater inhibition of clotting. The clinical consequence of a failure to reduce DOAC doses might be a higher rate of bleeding than in clinical trials, or potentially avoidable bleeding complications. While bleeding rates were not examined in this study, an increased risk of bleeding has been demonstrated for other anticoagulants when patients receive an excess dose in relation to estimated renal clearance. (25) Bleeding risks are also consistently highest in older patients, small patients and female patients.
As these are also the same patients for whom estimates of glomerular filtration are higher than In conclusion, substitution of GFR for estimated creatinine clearance can lead to a failure to recognize patients with non-valvular atrial fibrillation for whom reduced doses of DOACs are recommended as well as failure to recognize patients that should not receive edoxaban. The failure to recognize the indication for a DOAC dosage reduction could result in a greater risk of bleeding than seen in the DOAC randomized studies of efficacy and safety. For evaluation for edoxaban therapy for prevention of stroke in patients with atrial fibrillation, GFR corrected for BSA may improve patient selection. In the absence of DOAC concentration or pharmacologic effect data to guide dosing or data from clinical trials or FDA recommendations based on GFR, DOAC dosing adjustments based on renal function should be guided by estimates of creatinine clearance and not GFR. Author contributions: Janice B. Schwartz, MD was responsible for conception and design of the study, acquisition, analysis, and interpretation of data, drafting and revision of the manuscript and had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Janice Schwartz: study conception, design, data collection, data analysis, manuscript preparation.
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